Tonghua Dongbao Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Tonghua Dongbao Pharmaceutical Co., Ltd., founded in 1985, is a famous domestic pharmaceutical manufacturer integrating drug research and development, production and sales. It mainly researches and develops traditional Chinese patent medicines and simple preparations, chemical drugs and biological products. Its main products include Zhennaoning capsule, Dongbao Gantai tablet, recombinant human insulin - "Ganshulin", insulin glargine - "Pingshulin", aspartate insulin - "Ruishulin" and other series of products. In August 1994, the company was listed on the Shanghai Stock Exchange. Over the years, the company has established a scientific and technological research and development team with the development concept of "adhering to independent innovation and creating a world brand", and is committed to the research and development of drugs in diabetes and other therapeutic fields. In 1998, the first recombinant human insulin in China, Ganshulin, was successfully developed. This not only filled the domestic gap, but also made China the third country in the world, after the United States and Denmark, to produce recombinant human insulin, changing the long-term dependence of recombinant human insulin on foreign imports. This achievement won the second prize of the National Science and Technology Progress Award and was selected as one of the "Top 10 Science and Technology Progress News of China in 1998". The company has been awarded titles such as National Technology Innovation Demonstration Enterprise and National High tech Enterprise. The "Dongbao" and "Ganshulin" trademarks were recognized as well-known trademarks in China in 2002 and 2013, respectively. In June 2008, the transformation of the annual production of 3000 kilograms of recombinant human insulin raw material technology achievements was completed, becoming the first biopharmaceutical enterprise in China to pass the EU cGMP certification. In 2011, the company launched the research and development of the third generation insulin. In 2012, the third phase project of an annual production of 126 million recombinant human insulin injections was invested and constructed. In 2014, investment was made in the construction of production lines for insulin glargine and insulin aspartate. In 2016, investment and construction began in the Dongbao Biomedical Industrial Park, which includes Tonghua Dongbao Pharmaceutical Research Institute and Quality Testing Center, production bases for raw materials and injections of insulin and liraglutide, sewage treatment stations, and acetonitrile recovery workshops. Tonghua Dongbao Pharmaceutical Research Institute was officially put into use in March 2021. At present, the company's third-generation insulin - insulin glargine - was launched on the market in February 2020, and insulin aspartate was also launched in December 2021. The oral hypoglycemic drug "Siagliptin Phosphate Tablets" obtained a drug registration certificate in August 2021, "Siagliptin Metformin Tablets" obtained a drug registration certificate in October 2021, and Regagliptin Tablets received a production acceptance notice in June 2021. At the same time, the company focuses on aligning with the world and cooperates with the French company Adocia to jointly promote the research and development of the fourth generation insulin - fast acting insulin. In November 2020, a drug clinical trial approval notice was received from the National Drug Administration. In October 2021, the application for parallel phase I and phase III clinical trials was approved. This product is the first fourth generation insulin in China to obtain clinical permission to enter the clinical trial stage, and the first subject of the phase III clinical trial in China was enrolled in May 2022. The soluble glargine lysine double insulin injection was approved for domestic clinical trial application in March 2022, and for phase I clinical trial application in Germany in April 2022. This injection is currently the only compound formulation that can successfully combine long-acting glargine insulin and rapid acting lysine insulin. The company started the registration and certification of insulin glargine and insulin aspartate in the European Union and developing countries in early 2020. The company has five global first class innovative drugs, namely three innovative drugs in the field of diabetes treatment and two innovative drugs in the field of gout treatment, of which the world's first SGLT1/SGLT2/DPP4 three target inhibitor has been included in the first patient of China's Phase I clinical trial in February 2022; The URAT1 inhibitor (THDBH130 tablets), a new drug for gout/hyperuricemia, was clinically approved in December 2021. In April 2022, the first participant in the Chinese Phase I clinical trial was enrolled, which will inject strong impetus into the company's innovative development. |
| Headquarter | Tonghua |
| Establish Date | 12/28/1992 |
| Listed Code | 600867.SH |
| Listed Date | 8/24/1994 |
| Chairman | Cold spring is born. |
| CEO | Cold spring is born. |
| Website | www.thdb.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
